首页> 外国专利> METHOD administered to patients after a prosthetic repair of the tricuspid valve

METHOD administered to patients after a prosthetic repair of the tricuspid valve

机译:修复三尖瓣后给予患者的方法

摘要

1. A method for the management of patients after prosthesis tricuspid valve comprising a continuous constant use of warfarin and aspirin, and indications for use of heparin, fresh frozen plasma and vitamin K1, characterized in that the warfarin dose correction is performed depending on the value of international normalized ratio (MHO) in plasma venous blood, assuming the criterion of adequacy secondary target value MHO = 3 and in the range of not less than 2.5 and not more than 4.5. ! 2. A method according to claim 1, characterized in that at a value of not less than 2.0 MHO heparin cancel or not prescribed, and at least 2.0 MHO heparin administered to a patient, wherein the first continuous intravenous administration avtoshpritsem administered unfractionated heparin given body weight and age in a dose of 10 (children) to 100 (adults) u / kg, to achieve therapeutic indices activated partial (partial) thromboplastin time (aPTT) range from 60 to 75 s, and then proceeds to parenteral administration fraxiparin rate of 50 anti-Xa u / kg / 12 h ave and control between 0.2 and 0.4 anti-X activity, therapeutic aPTT indicators maintained in the range of from 60 to 75 seconds. ! 3. A method according to claim 2, characterized in that immediately after the operation prosthetic tricuspid valve heparin administered after receipt by reducing the rate of drainage tube is not less than 3-3.5 times as compared with the rate of wound on Incoming drainage tube to available in the first hour after surgery, the wound discharge flow of the drain tube must not exceed 0.5-1.0 mL / kg / h. ! 4. A method according to claim 2, characterized in that immediately after the operation of the prosthetic
机译:1.一种用于治疗三尖瓣假体后患者的方法,其包括连续不断地使用华法林和阿司匹林,以及使用肝素,新鲜冷冻血浆和维生素K1的适应症,其特征在于根据所述值进行华法林剂量校正假定血浆次要目标值MHO = 3,且在不小于2.5和不大于4.5的范围内,则应取血浆静脉血中国际标准化比率(MHO)的平均值。 ! 2.根据权利要求1所述的方法,其特征在于,以不小于2.0MHO的肝素或未开处方的肝素值,并且向患者施用至少2.0MHO的肝素,其中第一次连续静脉内施用阿伏托普生给定的肝素给体体重和年龄在10(儿童)至100(成人)u / kg的剂量下,以达到治疗指标活化的部分(部分)凝血活酶时间(aPTT)为60至75 s,然后进行非肠道应用fraxiparin 50次抗Xa u / kg / 12 h并控制0.2至0.4次抗X活性,治疗性aPTT指标维持在60至75秒的范围内。 ! 3.根据权利要求2所述的方法,其特征在于,在手术后立即通过减小引流管的速率将假体三尖瓣肝素给予后,与进入的引流管上的伤口缠绕率相比不小于3-3.5倍。在手术后的第一个小时内可用,引流管的伤口排出流量不得超过0.5-1.0 mL / kg / h。 ! 4.根据权利要求2所述的方法,其特征在于,在假体操作之后立即

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号